Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Cash & Current Investments: 2013-2025

Historic Cash & Current Investments for Fortress Biotech (FBIO) over the last 13 years, with Sep 2025 value amounting to $86.2 million.

  • Fortress Biotech's Cash & Current Investments rose 46.50% to $86.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $309.2 million, marking a year-over-year increase of 3.15%. This contributed to the annual value of $57.3 million for FY2024, which is 29.24% down from last year.
  • Per Fortress Biotech's latest filing, its Cash & Current Investments stood at $86.2 million for Q3 2025, which was up 15.91% from $74.4 million recorded in Q2 2025.
  • Over the past 5 years, Fortress Biotech's Cash & Current Investments peaked at $305.7 million during Q4 2021, and registered a low of $57.3 million during Q4 2024.
  • For the 3-year period, Fortress Biotech's Cash & Current Investments averaged around $82.9 million, with its median value being $78.0 million (2023).
  • Per our database at Business Quant, Fortress Biotech's Cash & Current Investments soared by 113.25% in 2021 and then tumbled by 68.64% in 2023.
  • Over the past 5 years, Fortress Biotech's Cash & Current Investments (Quarterly) stood at $305.7 million in 2021, then slumped by 41.69% to $178.3 million in 2022, then slumped by 54.60% to $80.9 million in 2023, then decreased by 29.24% to $57.3 million in 2024, then surged by 46.50% to $86.2 million in 2025.
  • Its last three reported values are $86.2 million in Q3 2025, $74.4 million for Q2 2025, and $91.3 million during Q1 2025.